All Sauce from Weekly Sauce:

THURSDAY, Nov. 9, 2023 (HealthDay News) – Researchers are testing a toothpaste that aims to let patients who are sensitive to peanuts and other foods simply brush their allergies away. Doctors already treat some food allergy patients with oral immunotherapy — feeding them tiny, portioned and gradually increasing bits of their allergen under supervision for…  read on >  read on >

A kinder, more thoughtful workplace can lead to better heart health among older employees, a new study finds. Older workers’ heart health risk factors decreased significantly when their office employed interventions designed to reduce work-family conflicts, researchers report in the Nov. 8 issue of the American Journal of Public Health. Specifically, their heart risk factors…  read on >  read on >

Strokes can strike anyone, but income and education may play a role in whether your stroke is fatal or disabling, new research shows. As reported Nov. 8 in the journal Neurology, folks who’d had a stroke were 10% more likely to die or become dependent on someone for their care if they were low-income or…  read on >  read on >

Eczema can be a burden on the mind as well the body, a new survey shows. People with eczema are more likely to experience depression and anxiety, and it worsens when additional allergic symptoms occur, according to a study to be presented Thursday at the American College of Allergy, Asthma and Immunology (ACAAI) annual meeting…  read on >  read on >

A second injectable diabetes drug has been approved for weight loss in overweight and obese adults, the U.S. Food and Drug Administration announced Wednesday. The weight-loss drug Zepbound contains the same active ingredient, tirzepatide, as the diabetes drug Mounjaro. Both medications are made by Eli Lilly and Co. “Obesity and overweight are serious conditions that…  read on >  read on >

WEDNESDAY, Nov. 8, 2023 (Healthday News) — A new drug to treat postpartum depression will cost nearly $16,000 for a 14-day course of treatment, a price tag that has doctors worried that some patients won’t be able to afford the medication. Zurzuvae (zuranolone) was first approved by the U.S. Food and Drug Administration back in August,…  read on >  read on >